K^(+)通道阻滞剂尼非卡兰联合酒石酸美托洛尔片对老年心律失常患者HRV的疗效  

Therapeutic effect of K^(+)channel blocker nifekalan combined metoprolol tartrate tablets on HRV in aged patients with arrhythmias

作　　者：罗卉[1] LUO Hui(Department of Cardiology,Second People's Hospital of Guangyuan City,Guangyuan,Sichuan,628017,China)

机构地区：[1]四川省广元市第二人民医院心血管内科,四川广元628017

出　　处：《心血管康复医学杂志》2022年第6期703-708,共6页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：四川省医学会重症医学(国瑞)专项课题[2017ZZ012(GR)]。

摘　　要：目的:探究K^(+)通道阻滞剂尼非卡兰联合酒石酸美托洛尔片对老年心律失常患者心率变异性(HRV)的疗效。方法:选择我院收治的老年心律失常患者124例,分为美托洛尔组和联合治疗组(在美托洛尔组治疗基础上采用尼非卡兰注射液治疗),各62例。治疗2周后,观察两组治疗前后心功能、24h动态心电图、心率变化、疗效及不良反应率。结果:与美托洛尔组相比,联合治疗组心功能显著改善,炎症相关指标显著降低,HRV指标:24h相邻RR间差>50ms百分数(PNN50)[(14.92±5.22)%比(28.71±6.25)%]、24h内每5min RR间期标准差均值(SDANN)[(80.52±16.23)ms比(98.35±20.15)ms]、24h相邻RR差值均方根(rMSSD)[(29.61±7.46)ms比(40.56±8.53)ms]、24h内正常RR间期标准差(SDNN)[(90.50±18.52)ms比(103.95±21.67)ms]均显著提高(P均=0.001)。联合治疗组总有效率显著高于美托洛尔组(98.39%比83.87%,P=0.040)。结论:老年心律失常患者联合应用尼非卡兰、酒石酸美托洛尔可显著改善心率变异性及炎症状态,提高心功能。Objective:To explore therapeutic effect of K^(+)channel blocker nifekalan combined metoprolol tartrate tablets on heart rate variability(HRV)in aged patients with arrhythmia.Methods:A total of 124 aged patients with arrhythmia treated in our hospital were randomly and equally divided into metoprolol group and combined treatment group(received nifekalan injection based on metoprolol group).After two-week treatment,cardiac function,24h ambulatory ECG,heart rate before and after treatment,therapeutic effect and incidence rate of adverse reactions were observed and compared between two groups.Results:Compared with metoprolol group,there were significant improvement in cardiac function and significant reduction in inflammatory related indexes,and significant rise in HRV indexes:adjacent normal RR interval difference>50ms stroke accounted for a percentage of 24h total RR interval(PNN50)[(14.92±5.22)%vs.(28.71±6.25)%],standard deviation of normal to normal RR intervals in all 5 min segments of the entire recording(SDANN)[(80.52±16.23)ms vs.(98.35±20.15)ms],root-mean square of differences between successive normal to normal intervals(rMSSD)[(29.61±7.46)ms vs.(40.56±8.53)ms]and standard deviation of normal to normal RR intervals calculated over the 24 h period(SDNN)[(90.50±18.52)ms vs.(103.95±21.67)ms]in combined treatment group,P=0.001 all.Total effective rate in combined treatment group was significantly higher than that of metoprolol group(98.39%vs.83.87%,P=0.040).Conclusion:K^(+)channel blocker nifekalan combined metoprolol tartrate can significantly improve heart rate variability,inflammation and cardiac function in aged patients with arrhythmia.

关 键 词：心律失常 心性 心率 钾通道阻滞剂 

分 类 号：R541.7[医药卫生—心血管疾病]